Endocannabinoid signaling and energy metabolism: A target for dietary intervention

Nutrition

Volumn 27, Issue 6, 2011, Pages 624-632

  Kim, Jeffrey ^a   Li, Yong ^a   Watkins, Bruce A ^a,b  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

3 fatty acids; Adipose; Arachidonic acid; Diabetes; Endocannabinoid signaling; Endocannabinoids; Insulin; Metabolic syndrome; Muscle; Obesity; Polyunsaturated fatty acids

Indexed keywords

ARACHIDONIC ACID; CHOLECYSTOKININ; DOCOSAHEXAENOIC ACID; ENDOCANNABINOID; FISH OIL; GHRELIN; GLUCOSE; ICOSAPENTAENOIC ACID; LEPTIN; LINOLEIC ACID; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; RIMONABANT;

ADIPOSE TISSUE; BODY FAT; CENTRAL NERVOUS SYSTEM FUNCTION; DIET THERAPY; DYSLIPIDEMIA; ENERGY BALANCE; ENERGY EXPENDITURE; ENERGY METABOLISM; FAT INTAKE; FOOD COMPOSITION; HORMONAL REGULATION; HUMAN; HYPOTHALAMUS; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID STORAGE; MACRONUTRIENT; METABOLIC REGULATION; METABOLIC SYNDROME X; MUSCLE METABOLISM; NEUROENDOCRINE SYSTEM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUTRITIONAL VALUE; OBESITY; PRIORITY JOURNAL; REVIEW; SATIETY; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; TISSUE SPECIFICITY; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION;

ADIPOSE TISSUE, WHITE; ANIMALS; CENTRAL NERVOUS SYSTEM; ENDOCANNABINOIDS; ENERGY METABOLISM; FATTY ACIDS, OMEGA-3; FATTY ACIDS, OMEGA-6; HUMANS; INSULIN RESISTANCE; LIGANDS; METABOLIC SYNDROME X; MUSCLE, SKELETAL; RECEPTORS, CANNABINOID; SATIETY RESPONSE; SIGNAL TRANSDUCTION;

ANIMALIA;

EID: 79955612810     PISSN: 08999007     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nut.2010.11.003     Document Type: Review

References (88)

1. Flegal K.M., Carroll M.D., Ogden C.L., Curtin L.R. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 2010, 303:235-241.
2. Kopelman P.G. Obesity as a medical problem. Nature 2000, 404:635-643.
3. Frayn K.N. Adipose tissue and the insulin resistance syndrome. Proc Nutr Soc 2001, 60:375-380.
4. Kahn S.E., Hull R.L., Utzschneider K.M. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 2006, 444:840-846.
5. Xu H., Barnes G.T., Yang Q., Tan G., Yang D., Chou C.J., et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003, 112:1821-1830.
6. Unger R.H. Lipid overload and overflow: metabolic trauma and the metabolic syndrome. Trends Endocrinol Metab 2003, 14:398-403.
7. Gaoni Y., Mechoulam R. Isolation, structure, and partial synthesis of an active constituent of hashish. J Am Chem Soc 1964, 86:1646-1647.
8. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990, 346:561-564.
9. Massa F., Storr M., Lutz B. The endocannabinoid system in the physiology and pathophysiology of the gastrointestinal tract. J Mol Med 2005, 83:944-954.
10. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992, 258:1946-1949.
11. Sugiura T., Kondo S., Sukagawa A., Nakane S., Shinoda A., Itoh K., et al. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 1995, 215:89-97.
12. Mechoulam R., Ben-Shabat S., Hanus L., Ligumsky M., Kaminski N.E., Schatz A.R., et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995, 50:83-90.
13. Deutsch D.G., Ueda N., Yamamoto S. The fatty acid amide hydrolase (FAAH). Prostaglandins Leukot Essent Fatty Acids 2002, 66:201-210.
14. Goparaju S.K., Ueda N., Taniguchi K., Yamamoto S. Enzymes of porcine brain hydrolyzing 2-arachidonoylglycerol, an endogenous ligand of cannabinoid receptors. Biochem Pharmacol 1999, 57:417-423.
15. Porter A.C., Sauer J.M., Knierman M.D., Becker G.W., Berna M.J., Bao J., et al. Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J Pharmacol Exp Ther 2002, 301:1020-1024.
16. Bisogno T., Melck D., Bobrov M.Y., Gretskaya N.M., Bezuglov V.V., De P.L., et al. N-acyl-dopamines: novel synthetic CB(1) cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. Biochem J 2000, 351(pt 3):817-824.
17. Di Marzo V., Goparaju S.K., Wang L., Liu J., Batkai S., Jarai Z., et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 2001, 410:822-825.
18. Walker J.M., Huang S.M., Strangman N.M., Tsou K., Sanudo-Pena M.C. Pain modulation by release of the endogenous cannabinoid anandamide. Proc Natl Acad Sci U S A 1999, 96:12198-12203.
19. Hampson R.E., Deadwyler S.A. Cannabinoids, hippocampal function and memory. Life Sci 1999, 65:715-723.
20. Herkenham M., Lynn A.B., Little M.D., Johnson M.R., Melvin L.S., de Costa B.R., et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A 1990, 87:1932-1936.
21. Gomez R., Navarro M., Ferrer B., Trigo J.M., Bilbao A., Del A.I., et al. A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J Neurosci 2002, 22:9612-9617.
22. Burdyga G., Lal S., Varro A., Dimaline R., Thompson D.G., Dockray G.J. Expression of cannabinoid CB1 receptors by vagal afferent neurons is inhibited by cholecystokinin. J Neurosci 2004, 24:2708-2715.
23. Liu Y.L., Connoley I.P., Wilson C.A., Stock M.J. Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice. Int J Obes (Lond) 2005, 29:183-187.
24. Cavuoto P., McAinch A.J., Hatzinikolas G., Janovska A., Game P., Wittert G.A. The expression of receptors for endocannabinoids in human and rodent skeletal muscle. Biochem Biophys Res Commun 2007, 364:105-110.
25. Bouret S.G., Simerly R.B. Minireview: leptin and development of hypothalamic feeding circuits. Endocrinology 2004, 145:2621-2626.
26. Di Marzo V., Matias I. Endocannabinoid control of food intake and energy balance. Nat Neurosci 2005, 8:585-589.
27. Kirkham T.C., Williams C.M., Fezza F., Di Marzo V. Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br J Pharmacol 2002, 136:550-557.
28. Inui A. Feeding and body-weight regulation by hypothalamic neuropeptides-mediation of the actions of leptin. Trends Neurosci 1999, 22:62-67.
29. Cota D., Marsicano G., Tschop M., Grubler Y., Flachskamm C., Schubert M., et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 2003, 112:423-431.
30. Horvath T.L. Endocannabinoids and the regulation of body fat: the smoke is clearing. J Clin Invest 2003, 112:323-326.
31. Williams C.M., Kirkham T.C. Anandamide induces overeating: mediation by central cannabinoid (CB1) receptors. Psychopharmacology (Berl) 1999, 143:315-317.
32. Izzo A.A., Mascolo N., Capasso F. The gastrointestinal pharmacology of cannabinoids. Curr Opin Pharmacol 2001, 1:597-603.
33. Jamshidi N., Taylor D.A. Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats. Br J Pharmacol 2001, 134:1151-1154.
34. Matias I., Gonthier M.P., Orlando P., Martiadis V., De Petrocellis L., Cervino C., et al. Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J Clin Endocrinol Metab 2006, 91:3171-3180.
35. D'Eon T.M., Pierce K.A., Roix J.J., Tyler A., Chen H., Teixeira S.R. The role of adipocyte insulin resistance in the pathogenesis of obesity-related elevations in endocannabinoids. Diabetes 2008, 57:1262-1268.
36. Cota D., Woods S.C. The role of the endocannabinoid system in the regulation of energy homeostasis. Curr Opin Endocrinol Diabetes 2005, 12:338-351.
37. Pagotto U., Marsicano G., Cota D., Lutz B., Pasquali R. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev 2006, 27:73-100.
38. Izzo A.A., Piscitelli F., Capasso R., Aviello G., Romano B., Borrelli F., et al. Peripheral endocannabinoid dysregulation in obesity: relation to intestinal motility and energy processing induced by food deprivation and re-feeding. Br J Pharmacol 2009, 158:451-461.
39. Parra D., Ramel A., Bandarra N., Kiely M., Martinez J.A., Thorsdottir I. A diet rich in long chain omega-3 fatty acids modulates satiety in overweight and obese volunteers during weight loss. Appetite 2008, 51:676-680.
40. Christensen R., Kristensen P.K., Bartels E.M., Bliddal H., Astrup A. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 2007, 370:1706-1713.
41. Berger A., Crozier G., Bisogno T., Cavaliere P., Innis S., Di Marzo V. Anandamide and diet: inclusion of dietary arachidonate and docosahexaenoate leads to increased brain levels of the corresponding N-acylethanolamines in piglets. Proc Natl Acad Sci U S A 2001, 98:6402-6406.
42. Watanabe S., Doshi M., Hamazaki T. N-3 polyunsaturated fatty acid (PUFA) deficiency elevates and n-3 PUFA enrichment reduces brain 2-arachidonoylglycerol level in mice. Prostaglandins Leukot Essent Fatty Acids 2003, 69:51-59.
43. Devane W.A., Axelrod J. Enzymatic synthesis of anandamide, an endogenous ligand for the cannabinoid receptor, by brain membranes. Proc Natl Acad Sci U S A 1994, 91:6698-6701.
44. Di Marzo V., Fontana A., Cadas H., Schinelli S., Cimino G., Schwartz J.C., et al. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 1994, 372:686-691.
45. Maki K.C., Reeves M.S., Farmer M., Griinari M., Berge K., Vik H., et al. Krill oil supplementation increases plasma concentrations of eicosapentaenoic and docosahexaenoic acids in overweight and obese men and women. Nutr Res 2009, 29:609-615.
46. Wood J.T., Williams J.S., Pandarinathan L., Janero D.R., Lammi-Keefe C.J., Makriyannis A. Dietary docosahexaenoic acid supplementation alters select physiological endocannabinoid-system metabolites in brain and plasma. J Lipid Res 2010, 51:1416-1423.
47. Matias I., Carta G., Murru E., Petrosino S., Banni S., Di Marzo V. Effect of polyunsaturated fatty acids on endocannabinoid and N-acyl-ethanolamine levels in mouse adipocytes. Biochim Biophys Acta 2008, 1781:52-60.
48. Batetta B., Griinari M., Carta G., Murru E., Ligresti A., Cordeddu L., et al. Endocannabinoids may mediate the ability of (n-3) fatty acids to reduce ectopic fat and inflammatory mediators in obese Zucker rats. J Nutr 2009, 139:1495-1501.
49. Di Marzo V., Griinari M., Carta G., Murru E., Ligresti A., Cordeddu L., et al. Dietary krill oil increases docosahexaenoic acid and reduces 2-arachidonoylglycerol but not N-acylethanolamine levels in the brain of obese Zucker rats. Int Dairy J 2010, 20:231-235.
50. Kabir M., Skurnik G., Naour N., Pechtner V., Meugnier E., Rome S., et al. Treatment for 2 mo with n 3 polyunsaturated fatty acids reduces adiposity and some atherogenic factors but does not improve insulin sensitivity in women with type 2 diabetes: a randomized controlled study. Am J Clin Nutr 2007, 86:1670-1679.
51. Thorsdottir I., Tomasson H., Gunnarsdottir I., Gisladottir E., Kiely M., Parra M.D., et al. Randomized trial of weight-loss-diets for young adults varying in fish and fish oil content. Int J Obes (Lond) 2007, 31:1560-1566.
52. Madsen L., Petersen R.K., Kristiansen K. Regulation of adipocyte differentiation and function by polyunsaturated fatty acids. Biochim Biophys Acta 2005, 1740:266-286.
53. Perez-Matute P., Marti A., Martinez J.A., Fernandez-Otero M.P., Stanhope K.L., Havel P.J., et al. Eicosapentaenoic fatty acid increases leptin secretion from primary cultured rat adipocytes: role of glucose metabolism. Am J Physiol Regul Integr Comp Physiol 2005, 288:R1682-R1688.
54. Peyron-Caso E., Taverna M., Guerre-Millo M., Veronese A., Pacher N., Slama G., et al. Dietary (n-3) polyunsaturated fatty acids up-regulate plasma leptin in insulin-resistant rats. J Nutr 2002, 132:2235-2240.
55. Ravinet Trillou C., Delgorge C., Menet C., Arnone M., Soubrie P. CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int J Obes Relat Metab Disord 2004, 28:640-648.
56. Wang Y.H., Tache Y., Sheibel A.B., Go V.L., Wei J.Y. Two types of leptin-responsive gastric vagal afferent terminals: an in vitro single-unit study in rats. Am J Physiol Regul Integr Comp Physiol 1997, 273:R833-R837.
57. Tucci S.A., Rogers E.K., Korbonits M., Kirkham T.C. The cannabinoid CB1 receptor antagonist SR141716 blocks the orexigenic effects of intrahypothalamic ghrelin. Br J Pharmacol 2004, 143:520-523.
58. Engeli S., Bohnke J., Feldpausch M., Gorzelniak K., Janke J., Batkai S., et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes 2005, 54:2838-2843.
59. Osei-Hyiaman D., Depetrillo M., Pacher P., Liu J., Radaeva S., Batkai S., et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 2005, 115:1298-1305.
60. Cote M., Matias I., Lemieux I., Petrosino S., Almeras N., Despres J.P., et al. Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men. Int J Obes (Lond) 2007, 31:692-699.
61. Kershaw E.E., Flier J.S. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004, 89:2548-2556.
62. Bjorbaek C., Kahn B.B. Leptin signaling in the central nervous system and the periphery. Recent Prog Horm Res 2004, 59:305-331.
63. Munzberg H., Bjornholm M., Bates S.H., Myers M.G. Leptin receptor action and mechanisms of leptin resistance. Cell Mol Life Sci 2005, 62:642-652.
64. Gonzalez-Periz A., Horrillo R., Ferre N., Gronert K., Dong B., Moran-Salvador E., et al. Obesity-induced insulin resistance and hepatic steatosis are alleviated by omega-3 fatty acids: a role for resolvins and protectins. FASEB J 2009, 23:1946-1957.
65. Weyer C., Funahashi T., Tanaka S., Hotta K., Matsuzawa Y., Pratley R.E., et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001, 86:1930-1935.
66. Yamauchi T., Kamon J., Waki H., Terauchi Y., Kubota N., Hara K., et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001, 7:941-946.
67. Yan Z.C., Liu D.Y., Zhang L.L., Shen C.Y., Ma Q.L., Cao T.B., et al. Exercise reduces adipose tissue via cannabinoid receptor type 1 which is regulated by peroxisome proliferator-activated receptor-delta. Biochem Biophys Res Commun 2007, 354:427-433.
68. Bluher M., Engeli S., Kloting N., Berndt J., Fasshauer M., Batkai S., et al. Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes 2006, 55:3053-3060.
69. Bensaid M., Gary-Bobo M., Esclangon A., Maffrand J.P., Le F.G., Oury-Donat F., et al. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol 2003, 63:908-914.
70. Wellen K.E., Hotamisligil G.S. Obesity-induced inflammatory changes in adipose tissue. J Clin Invest 2003, 112:1785-1788.
71. Weisberg S.P., McCann D., Desai M., Rosenbaum M., Leibel R.L., Ferrante A.W. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003, 112:1796-1808.
72. Raederstorff D., Moser U. Influence of an increased intake of linoleic acid on the incorporation of dietary (n-3) fatty acids in phospholipids and on prostanoid synthesis in rat tissues. Biochim Biophys Acta 1992, 1165:194-200.
73. Lands W.E. Biosynthesis of prostaglandins. Annu Rev Nutr 1991, 11:41-60.
74. Pagano C., Pilon C., Calcagno A., Urbanet R., Rossato M., Milan G., et al. The endogenous cannabinoid system stimulates glucose uptake in human fat cells via phosphatidylinositol 3-kinase and calcium-dependent mechanisms. J Clin Endocrinol Metab 2007, 92:4810-4819.
75. Sparling P.B., Giuffrida A., Piomelli D., Rosskopf L., Dietrich A. Exercise activates the endocannabinoid system. Neuroreport 2003, 14:2209-2211.
76. Kim J.Y., Nolte L.A., Hansen P.A., Han D.H., Ferguson K., Thompson P.A., et al. High-fat diet-induced muscle insulin resistance: relationship to visceral fat mass. Am J Physiol Regul Integr Comp Physiol 2000, 279:R2057-R2065.
77. Shimomura I., Hammer R.E., Ikemoto S., Brown M.S., Goldstein J.L. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature 1999, 401:73-76.
78. Petersen K.F., Oral E.A., Dufour S., Befroy D., Ariyan C., Yu C., et al. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J Clin Invest 2002, 109:1345-1350.
79. Ravinet T.C., Arnone M., Delgorge C., Gonalons N., Keane P., Maffrand J.P., et al. Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol 2003, 284:R345-R353.
80. Hayashi T., Boyko E.J., McNeely M.J., Leonetti D.L., Kahn S.E., Fujimoto W.Y. Visceral adiposity, not abdominal subcutaneous fat area, is associated with an increase in future insulin resistance in Japanese Americans. Diabetes 2008, 57:1269-1275.
81. Matias I., Petrosino S., Racioppi A., Capasso R., Izzo A.A., Di M.V. Dysregulation of peripheral endocannabinoid levels in hyperglycemia and obesity: effect of high fat diets. Mol Cell Endocrinol 2008, 286:S66-S78.
82. Esposito I., Proto M.C., Gazzerro P., Laezza C., Miele C., Alberobello A.T., et al. The cannabinoid CB1 receptor antagonist rimonabant stimulates 2-deoxyglucose uptake in skeletal muscle cells by regulating the expression of phosphatidylinositol-3-kinase. Mol Pharmacol 2008, 74:1678-1686.
83. Eckardt K., Sell H., Taube A., Koenen M., Platzbecker B., Cramer A., et al. Cannabinoid type 1 receptors in human skeletal muscle cells participate in the negative crosstalk between fat and muscle. Diabetologia 2009, 52:664-674.
84. Murdolo G., Kempf K., Hammarstedt A., Herder C., Smith U., Jansson P.A. Insulin differentially modulates the peripheral endocannabinoid system in human subcutaneous abdominal adipose tissue from lean and obese individuals. J Endocrinol Invest 2007, 30:RC17-RC21.
85. Di Marzo V., Verrijken A., Hakkarainen A., Petrosino S., Mertens I., Lundbom N., et al. Role of insulin as a negative regulator of plasma endocannabinoid levels in obese and nonobese subjects. Eur J Endocrinol 2009, 161:715-722.
86. Di Marzo V., Cote M., Matias I., Lemieux I., Arsenault B.J., Cartier A., et al. Changes in plasma endocannabinoid levels in viscerally obese men following a 1 year lifestyle modification programme and waist circumference reduction: associations with changes in metabolic risk factors. Diabetologia 2009, 52:213-217.
87. Suzuki K., Kono T. Evidence that insulin causes translocation of glucose transport activity to the plasma membrane from an intracellular storage site. Proc Natl Acad Sci U S A 1980, 77:2542-2545.
88. Lazar M.A. How obesity causes diabetes: not a tall tale. Science 2005, 307:373-375.